针对发性区域的纳米颗粒药物输送系统用于抗发作药物
Honglu Ping1, Qi Zhang2, Xiaojie Chen2
1Department of Neurology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China.
Materials today. Bio
|September 29, 2025
概括
这项研究引入了一种用于治疗的创新药物输送系统. 该系统使用电刺激在需要时释放抗发作药物,提高疗效并向受影响的大脑区域.
科学领域:
- 神经学 神经学
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
背景情况:
- 影响全球超过6500万,其特点是过度的神经元刺激.
- 传统的抗发作药物 (ASM),如氨酸 (PHT),由于血脑屏障 (BBB) 透和毒性差,其疗效有限.
- 在中,托芬 (Trp) 的新陈代谢发生变化,导致耗和新陈代谢被困在发性区域.
研究的目的:
- 开发一个电响应的,闭环药物递送系统 (DDS),用于增强治疗.
- 为了利用聚烯 (PPY) 纳米粒子在电刺激中触发的按需PHT释放.
- 纳入氨酸 (HA) 以有针对性的输送和延长在发性区域的保留.
主要方法:
- 用PHT装载的电响应PPY纳米颗粒的制造.
- 整合Trp和HA以提高准和保留.
- 电刺激诱导的PPY纳米粒子收缩和药物释放的演示.
- 评估"代谢陷"和"有针对性的分娩延长保留"的影响.
主要成果:
- 开发的DDS显示了对按需药物释放的电响应.
- PPY-HA-PHT-Trp纳米颗粒显示出有针对性传递和在损伤部位长时间保留的潜力.
- 该系统利用PHT,Trp代谢和HA-CD44相互作用来增强治疗效果.
结论:
- 拟议的非侵入性DDS提供了一种新的管理方法.
- 该系统有潜力通过克服BBB的局限性和减少非目标毒性来提高ASM的疗效.
- 该PPY-HA-PHT-Trp DDS显示未来临床应用在治疗的承诺.
更多相关视频
相关概念视频
Antiepileptic Drugs: Sodium Channel Blockers
1.6K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.6K
Antiepileptic Drugs: Potassium Channel Activators
635
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
635
Antiepileptic Drugs: Calcium Channel Blockers
1.2K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.2K
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
827
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
827
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K


